Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer

被引：0
|
作者：
Chang, Lei [1 ,2 ,3 ]
Graham, Peter H. [1 ,2 ,3 ]
Hao, Jingli [1 ,2 ,3 ]
Jie Ni [1 ,2 ,3 ]
Bucci, Joseph [1 ,2 ,3 ]
Cozzi, Paul J. [1 ,2 ,3 ,4 ]
Kearsley, John H. [1 ,2 ,3 ]
Li, Yong [1 ,2 ,3 ]
机构：
[1] St George Hosp, Canc Care Ctr, Sydney, NSW, Australia
[2] St George Hosp, Prostate Canc Inst, Sydney, NSW, Australia
[3] Univ New S Wales, Fac Med, St George & Sutherland Clin Sch, Kensington, NSW 2033, Australia
[4] St George Hosp, Dept Surg, Sydney, NSW, Australia
来源：
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | 2014年 / 34卷
关键词：
Prostate cancer; radiation therapy; radioresistance; PI3K/Akt/mTOR inhibitor; cancer stem cell;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
281
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [21] REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFIELDS) THROUGH ACTIVATION OF THE PI3K/AKT/MTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/MTOR DUAL INHIBITORS
    Klein-Goldberg, Anat
    Voloshin, Tali
    Zemer-Tov, Efrat
    Paz, Rom
    Koren, Lilach
    Wainer-Katsir, Kerem
    Volodin, Alexandra
    Koltun, Bella
    Brant, Boris
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2021, 23 : 84 - 84
  • [22] Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management
    Adhami, Vaqar Mustafa
    Syed, Deeba Nadeem
    Khan, Naghma
    Mukhtar, Hasan
    BIOCHEMICAL PHARMACOLOGY, 2012, 84 (10) : 1277 - 1281
  • [23] Combined perifosine (PI3K/AKT inhibitor) and radiotherapy for prostate cancer
    Gao, Y.
    Wang, X.
    Zhu, J.
    Mai, W.
    Huang, Y.
    Floryk, D.
    Ittmann, M.
    Butler, E. B.
    Teh, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S712 - S713
  • [24] PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
    Wu, P.
    Hu, Y-Z
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) : 4326 - 4341
  • [25] Phytochemicals as PI3K/Akt/mTOR Inhibitors and Their Role in Breast Cancer Treatment
    Narayanankutty, Arunaksharan
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2020, 15 (03) : 188 - 199
  • [26] Evaluation of nab-sirolimus in combination with PI3K pathway inhibitors to overcome PI3K/mTOR resistance in PI3K-mutant breast cancer cell lines
    Wallace, Sean
    Myint, Khine Nyein
    Hou, Shihe
    Zalath, Maria
    Kwon, Andrew
    McMorran, Brain
    Vivanco, Igor
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [27] Design and synthesis of dual PI3K/mTor inhibitors
    Olivero, Alan
    Heffron, Timothy
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Chang, Christine
    Dotson, Jennafer
    Friedman, Lori
    Goldsmith, Richard
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Nonomiya, Jim
    Pang, Jodie
    Peterson, David
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Daniel
    Tsui, Vickie
    Ultsch, Mark
    Wang, Shumei
    Wiesmann, Christian
    Wong, Susan
    Zhu, Bing-Yan
    Chuckowree, Irina
    Folkes, Adrian
    Shuttleworth, Steve
    CANCER RESEARCH, 2009, 69
  • [28] Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer
    Heller, Simon
    Sugawara, Tatsuo
    Nevedomskaya, Ekaterina
    Baumgart, Simon J.
    Nguyen, Holly
    Corey, Eva
    Bohme, Annika
    von Ahsen, Oliver
    Politz, Oliver
    Haendler, Bernard
    CANCER RESEARCH, 2023, 83 (11)
  • [29] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [30] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
12345